Biomarkers and Parkinson's Disease: Bringing Earlier Diagnosis Within Reach

One of the greatest challenges in Parkinson's disease is that diagnosis often occurs after significant neurological changes have already taken place. Researchers now believe the disease may begin years—or even decades—before the motor symptoms that typically trigger clinical evaluation. By the time symptoms appear, most patients have lost 60% to 80% or more of the dopamine-producing cells in the substantia nigra. This growing understanding has intensified the search for reliable biomarkers that could improve diagnosis, monitor disease progression, guide clinical trial recruitment, and support the development of new therapies.

For decades, Parkinson’s disease has largely been diagnosed through clinical observation of symptoms such as tremor, rigidity, bradykinesia, and postural instability. While treatment advances have improved symptom management, researchers increasingly recognize that the biological processes underlying the disease begin long before many patients seek medical attention.

Biomarkers—measurable biological, imaging, or digital indicators—may help bridge this gap by providing objective signals of disease activity. As research advances, biomarkers are becoming increasingly important not only for understanding Parkinson's disease itself, but also for improving how clinical studies are designed and conducted. In Parkinson's disease, biomarker research generally focuses on biological markers such as alpha-synuclein, blood-based biomarkers, imaging approaches, and digital measures generated through connected devices.

The Need for Early Detection

One of the defining pathological hallmarks of Parkinson's disease is the accumulation of misfolded alpha-synuclein proteins, commonly found in Lewy bodies and Lewy neurites. Over time, these abnormal protein aggregates are believed to affect multiple regions of the nervous system, contributing to progressive neuronal dysfunction and the emergence of both motor and nonmotor symptoms.

Many individuals who later develop Parkinson's disease experience nonmotor symptoms—including loss of smell, REM sleep behavior disorder, constipation, fatigue, and mood changes—years before motor symptoms appear. This period, known as the prodromal stage of Parkinson’s disease, represents a potentially important window for intervention and an area of intense research interest because it may offer insight into the earliest biological changes associated with the disease.

The challenge for researchers is determining which of these biological changes can be measured reliably enough to improve disease identification, monitoring, and therapeutic development.

Alpha-Synuclein: A Leading Biomarker Candidate

Among the many biomarker candidates under investigation, alpha-synuclein has emerged as one of the most significant because of its close association with Parkinson's disease pathology.

Recent advances have led to the development of alpha-synuclein seed amplification assays (SAAs), specialized tests capable of detecting abnormal forms of the protein in biological samples such as cerebrospinal fluid. Studies have demonstrated promising results in differentiating individuals with Parkinson's disease from healthy controls and certain related neurological disorders. 

The growing interest in alpha-synuclein biomarkers extends beyond their potential diagnostic value. Researchers hope these assays may provide deeper insight into disease biology and help identify patients who share common underlying pathological features.

Despite encouraging progress, important limitations remain. Alpha-synuclein assays are not yet broadly standardized, may not identify all forms of Parkinson's disease, and are not currently considered standalone diagnostic tools. Additional validation will be necessary before routine clinical implementation.

Expanding the Search: Blood-Based Biomarkers

While cerebrospinal fluid assays have generated considerable interest, their collection requirements may limit widespread adoption. As a result, researchers are actively pursuing blood-based biomarkers that could provide a more practical and scalable approach.

Current investigations include biomarkers associated with neurodegeneration, inflammation, protein misfolding, and genetic susceptibility. Several research groups are exploring whether alpha-synuclein, neurofilament light chain, inflammatory markers, and other molecular signatures can be detected reliably through blood-based testing. Advances in laboratory technologies continue to improve researchers' ability to detect subtle biological signals previously difficult to measure.

For biotechnology companies, diagnostic developers, and clinical researchers, a validated blood-based biomarker could offer significant operational advantages. Less invasive testing could simplify participant recruitment, facilitate longitudinal monitoring, and potentially support larger clinical research programs.

Although significant scientific challenges remain, blood-based testing represents one of the most active areas of Parkinson's biomarker research.

Digital Biomarkers and Continuous Monitoring

Not all biomarkers are biological. 

The growth of wearable technologies and digital health platforms has created opportunities to measure how Parkinson's disease affects patients in real-world settings. Smartwatches and wearable motion sensors can continuously collect data on movement patterns, tremor severity, mobility, sleep quality, and other functional measures.

Unlike biological biomarkers, which seek to identify disease-associated processes, digital biomarkers are designed to capture how disease affects day-to-day function. This continuous stream of information may provide a more comprehensive picture than periodic clinical visits alone.

Artificial intelligence and machine learning tools may further enhance the value of digital biomarkers by helping researchers identify patterns and trends that are difficult to detect through traditional clinical assessments. As these technologies mature, they may become increasingly important tools for monitoring disease progression and evaluating treatment response.

Implications for Drug Development

Biomarkers may have their greatest impact in clinical development. 

One of the most significant challenges in Parkinson's disease research is identifying patients at the appropriate stage of disease for clinical trial participation. Because Parkinson's disease is highly heterogeneous, patients enrolled in the same study may have different underlying biology, rates of progression, and treatment responses.

Biomarkers have the potential to help address these challenges by supporting earlier patient identification, improving patient stratification, and creating more homogeneous study populations. Researchers may also be able to use biomarkers to evaluate biological responses to investigational therapies alongside traditional clinical endpoints. In addition, biomarkers may provide more objective measures of disease activity than symptom-based assessments alone, helping researchers evaluate therapeutic impact with greater precision.

More precise biomarkers could improve trial efficiency, reduce screen-failure rates, support earlier-stage intervention studies, and provide researchers with objective measures of disease activity. If validated, these capabilities could help accelerate the evaluation of potential disease-modifying therapies. 

Challenges and Regulatory Considerations

Despite growing enthusiasm, substantial scientific and regulatory challenges remain.

No validated biomarker-based diagnostic framework has yet replaced traditional clinical diagnosis. Researchers must continue to demonstrate analytical validity, reproducibility, clinical validity, and clinical utility across diverse patient populations before many of these tools can gain broad acceptance.

Regulators have recognized the potential importance of biomarkers in drug development. In 2024, the U.S. Food and Drug Administration issued a Letter of Support encouraging further study of alpha-synuclein seed amplification assays as biomarkers for patient selection in clinical investigations involving synuclein-related neurodegenerative disorders. However, regulatory interest should not be mistaken for regulatory approval, and substantial validation work remains ahead.

Digital biomarkers introduce additional considerations involving data quality, privacy, cybersecurity, software validation, and regulatory oversight. Organizations pursuing these technologies must balance innovation with appropriate safeguards to maintain patient trust and regulatory compliance.

Looking Ahead

Parkinson's disease research is gradually shifting from a framework defined primarily by observable symptoms toward one increasingly informed by measurable biological and digital signals.

Advances in alpha-synuclein assays, blood-based testing, and digital monitoring technologies are providing researchers with new tools to better understand disease biology, monitor progression, and improve the efficiency of clinical development programs.

While significant scientific, operational, and regulatory challenges remain, biomarkers may ultimately help move the field toward more precise and data-driven approaches to Parkinson's disease research and treatment.

For life sciences organizations, the opportunity extends beyond earlier diagnosis to the broader possibility of more efficient clinical trials, improved patient stratification, and a deeper understanding of the disease itself. As biomarker science continues to mature, organizations developing diagnostics, therapeutics, and digital health technologies will need to navigate evolving scientific, regulatory, and operational requirements while positioning themselves to capitalize on new opportunities for precision medicine.

Authored by Jeffrey Pirog, Berkley Life Sciences Summer Intern